Valneva SE (VALN): CEO Lingelbach interview (2021-NOV-23) P...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	1
Posts	431
Boards Moderated	0
Alias Born	09/27/2006

Re: None

Tuesday, 11/23/2021 1:30:59 PM

Tuesday, November 23, 2021 1:30:59 PM

CEO Lingelbach interview (2021-NOV-23) Part II

profil: How well does VLA2001 work compared to the already approved vaccines?

Lingelbach: We compared our vaccine candidate VLA2001 with AstraZeneca's vaccine in the phase 3 trial. VLA2001 proved superior in terms of neutralizing antibody titers, had a significantly better tolerability profile, and was non-inferior in terms of seroconversion rates (i.e., the percentage of individuals who form specific immunity after vaccination).
We believe that VLA2001 may offer advantages over currently licensed vaccines in terms of safety, cost, ease of manufacture, and distribution.
Inactivated vaccines meet standard cold chain requirements (two to eight degrees Celsius), making them easier to store and distribute than mRNA vaccines.

profil: And in terms of safety?

Lingelbach: In the AstraZeneca comparative study, participants who were 30 years and older reported significantly fewer adverse events up to seven days after vaccination.